LifeGlue Technologies
Founded 2024
About LifeGlue Technologies
LifeGlue Technologies is a Finnish spin-out from Tampere University advancing Glue4Life, a clinical-grade hyaluronic-acid bioink/hydrogel engineered for translational use. Rooted in rigorous, peer-reviewed science, Glue4Life enables high-fidelity 3D bioprinting of human tissues and organs and is designed to support clinical pathways for implantable constructs and advanced therapies. The platform’s reproducibility and ISO 13485/GMP-aligned documentation help ATMP developers move from R&D to manufacturing with fewer CMC risks. LifeGlue owns its core IP, has achieved first sales and active pilots, and partners with OEMs and leading labs to standardize the raw materials underpinning next-generation regenerative medicine.
Company Facts
- Founded: 2024
- Legal name: LifeGlue Technologies Oy
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $75.3K
- Last round: Grant (Jan 2026)
- Website: http://www.Glue4life.com
- Phone: 00358405776464
Social Profiles
Canonical: https://fsome.com/organization/lifeglue-technologies-8255421 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.